Presentations to Highlight Patient Experience Research, AURA-IPF Phase 2 Trial Design for AP02, and Long-Term Safety Data for AP01BOSTON, Oct.…
REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel…
WELLINGTON, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Medical Specialists of the Palm Beaches (MSPB), a primary care-focused, multi-specialty physician…
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of…
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak®…
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension…
Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate…
Company to Exhibit at American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting 2025DALLAS, Oct. 21, 2025 (GLOBE NEWSWIRE)…
BENTONVILLE, Ark., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced the appointment of Mark Schaftlein…